Back to top
more

Amphastar Pharmaceuticals (AMPH)

(Delayed Data from NSDQ)

$21.21 USD

21.21
440,154

+0.26 (1.24%)

Updated Aug 1, 2025 04:00 PM ET

After-Market: $21.21 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Generic Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

BridgeBio Pharma (BBIO) Moves 75.9% Higher: Will This Strength Last?

by Zacks Equity Research

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) closed the most recent trading day at $55.87, moving +1.07% from the previous trading session.

Zacks Equity Research

Here's Why Investors Should Add Encompass Health (EHC) to Portfolio

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of solid demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

Zacks Equity Research

Amphastar (AMPH) is an Incredible Growth Stock: 3 Reasons Why

by Zacks Equity Research

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Align Technology (ALGN) and Amphastar Pharmaceuticals (AMPH) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights include PDD Holdings, Amphastar Pharmaceuticals and Suzano

by Zacks Equity Research

PDD Holdings, Amphastar Pharmaceuticals and Suzano are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

3 Profitable Stocks Worth Investing in Using Net Income Ratio

by Tirthankar Chakraborty

PDD Holdings (PDD), Amphastar Pharmaceuticals (AMPH) and Suzano (SUZ) are some of the top picks with a high net income ratio.

Zacks Equity Research

Amphastar Pharmaceuticals (AMPH) Is Up 0.54% in One Week: What You Should Know

by Zacks Equity Research

Does Amphastar Pharmaceuticals (AMPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Factors That Make HCA Healthcare (HCA) a Lucrative Bet Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on the resumption of elective surgeries, acquisitions and strong cash-generation abilities.

Zacks Equity Research

3 Reasons Growth Investors Will Love Amphastar (AMPH)

by Zacks Equity Research

Amphastar (AMPH) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Equity Research

Are Medical Stocks Lagging Amphastar Pharmaceuticals (AMPH) This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Tirthankar Chakraborty headshot

4 Top-Ranked Profitable Stocks to Buy Using Net Income Ratio

by Tirthankar Chakraborty

PDD Holdings Inc. (PDD), Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH) and Axon Enterprise (AXON) have been selected as the top picks with a high net income ratio.

Zacks Equity Research

Centene (CNC) Divests Apixio to Boost Its Core Business

by Zacks Equity Research

Centene (CNC) completes the sale of Apixio to New Mountain Capital in a bid to dispose of non-core assets and grow its core Managed Care business.

Zacks Equity Research

Centene (CNC) to Provide Managed Care for SoonerSelect Program

by Zacks Equity Research

Centene (CNC) wins managed care contract to serve people in Oklahoma through the SoonerSelect and SoonerSelect Children's Specialty Plan programs.

Zacks Equity Research

Here is Why Growth Investors Should Buy Amphastar (AMPH) Now

by Zacks Equity Research

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Zacks Equity Research

Is Amphastar Pharmaceuticals (AMPH) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.

Zacks Equity Research

Zacks.com featured highlights include Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings

by Zacks Equity Research

Tecnoglass, Amphastar Pharmaceuticals, Turkcell Iletisim Hizmetleri, and Copa Holdings are part of the Zacks Screen of the Week article.

Tirthankar Chakraborty headshot

4 Solid Profitable Stocks to Invest in Using Net Income Ratio

by Tirthankar Chakraborty

Tecnoglass (TGLS), Amphastar Pharmaceuticals (AMPH), Turkcell Iletisim Hizmetleri (TKC) and Copa Holdings (CPA) have been selected as the top picks with a high net income ratio.

Zacks Equity Research

Tenet Healthcare (THC) Gains 42.1% YTD: More Room to Run?

by Zacks Equity Research

Tenet Healthcare's (THC) aim to boost USPI's network through continuous buyouts is positioning the company well for growth.

Zacks Equity Research

Factors That Make Ensign Group (ENSG) a Lucrative Bet Now

by Zacks Equity Research

Ensign Group (ENSG) is well-poised for growth on increasing service revenues, an expanding healthcare portfolio and a strong capital position.

Zacks Equity Research

Here's Why You Should Hold UnitedHealth Group (UNH) Stock Now

by Zacks Equity Research

Membership growth, expanding government business and improving operating margin poise UnitedHealth Group (UNH) well for growth.

Zacks Equity Research

Zacks Industry Outlook Highlights Amphastar, Dr. Reddy's and Teva Pharmaceutical

by Zacks Equity Research

Amphastar, Dr. Reddy's and Teva Pharmaceutical have been highlighted in this Industry Outlook article.

Zacks Equity Research

Looking for a Growth Stock? 3 Reasons Why Amphastar (AMPH) is a Solid Choice

by Zacks Equity Research

Amphastar (AMPH) possesses solid growth attributes, which could help it handily outperform the market.

Sundeep Ganoria headshot

3 Generic Drug Stocks to Watch Amid Macro Headwinds

by Sundeep Ganoria

The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry persists. New product launches provide some respite to AMPH, RDY and TEVA.

Zacks Equity Research

Is Amphastar Pharmaceuticals (AMPH) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Amphastar Pharmaceuticals (AMPH) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.